Phase II trial of trimetrexate in patients with advanced soft-tissue sarcoma
✍ Scribed by Jonathan D. Licht; René Gonin; Karen H. Antman
- Publisher
- Springer
- Year
- 1991
- Tongue
- English
- Weight
- 241 KB
- Volume
- 28
- Category
- Article
- ISSN
- 0344-5704
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Thirty-six previously treated adult patients with advanced soft tissue sarcomas received CPDD 120 mg/m2 with mannitol diuresis. There were only two (6%) partial responses and five (15%) minor responses in 34 evaluable patients. Toxicity included nausea and vomiting, myelosuppression, mild ototoxicit
Thirty-four patients with advanced soft tissue sarcomas were entered in a phase II trial of echinomycin. Patients received 1.2 mg/m 2 intravenously (i.v.) weekly times four followed by a two week rest period. There were no objective responses. Dose limiting toxicity was gastrointestinal. Echinomycin